Acorda Therapeutics, Inc. Sustainability Profile
Acorda Therapeutics, Inc., a leading biotechnology company based in the United States, focuses on developing innovative therapies for neurological disorders. Founded in 1995, Acorda has made significant strides in the industry, particularly with its core products aimed at improving mobility and quality of life for patients with conditions such as multiple sclerosis and spinal cord injury. Headquartered in Ardsley, New York, Acorda operates primarily in the US, with a commitment to advancing scientific research and clinical development. The company’s flagship products, including Ampyra, are distinguished by their unique mechanisms of action that enhance walking ability in patients. Acorda's dedication to innovation and patient-centric solutions has solidified its position as a notable player in the biotechnology sector, contributing to advancements in neurological care.
DitchCarbon Score
How does Acorda Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Acorda Therapeutics, Inc.'s score of 25 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Acorda Therapeutics, Inc.'s reported carbon emissions
Acorda Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As of now, Acorda Therapeutics has not inherited any emissions data from a parent or related organization, nor does it have any cascading climate initiatives from other entities. This lack of data suggests that the company may still be in the early stages of developing its climate commitments or reporting practices. In the context of the biopharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction strategies. Acorda Therapeutics may benefit from aligning with industry standards and setting measurable targets to enhance its environmental impact and transparency in the future.
How Carbon Intensive is Acorda Therapeutics, Inc.'s Industry?
How Carbon Intensive is Acorda Therapeutics, Inc.'s Location?
Acorda Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Acorda Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
